Results 171 to 180 of about 952 (211)
Some of the next articles are maybe not open access.
Renal outcomes with dipeptidyl peptidase-4 inhibitors
Diabetes & Metabolism, 2018Dipeptidyl peptidase-4 inhibitors (DPP-4is) are increasingly being used in the management of type 2 diabetes (T2D). The present review summarizes the current knowledge of the effects of DPP-4is on renal outcomes by analyzing the experimental preclinical data, the effects of DPP-4is on urinary albumin-creatinine ratios (UACRs) and estimated glomerular ...
Scheen, André, DELANAYE, Pierre
openaire +3 more sources
The effects of dipeptidyl peptidase‐4 inhibitors on kidney outcomes
Diabetes, Obesity and Metabolism, 2020Abstract Aims To summarize evidence from randomized controlled trials (RCTs) concerning the effects of dipeptidyl peptidase‐4 (DPP‐4) inhibitors on kidney outcomes in patients with type 2 diabetes mellitus (T2DM). Methods
Daniel V. O'Hara +5 more
openaire +2 more sources
Dipeptidyl peptidase-4 inhibitors
2016Dipeptidyl peptidase (DPP)-4 inhibitors inhibit the activity of the enzyme responsible for the initial rapid degradation of the incretin hormones, thereby enhancing their antihyperglycemic effects.
openaire +1 more source
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Highlights: Introduction Pharmacology Treatment Advantages/Disadvantages Therapeutic Considerations Monographs ...Kimberly C. McKeirnan +1 more
+4 more sources
Dipeptidyl Peptidase-4 Inhibitors and Their Effects on the Cardiovascular System
Current Cardiology Reports, 2013It is well known that patients with type 2 diabetes mellitus (T2DM) are at increased risk of cardiovascular (CV) disease. Elevated plasma glucose levels that independently lead to increased cardiovascular risk, combined with associated co-morbidities such as obesity, hypertension, and dyslipidemia, further contribute to the development of CV ...
B, Solun, D, Marcoviciu, D, Dicker
openaire +2 more sources
Dipeptidyl peptidase‐4 inhibitors and angioedema: a class effect?
Diabetic Medicine, 2013AbstractBackgroundDipeptidyl peptidase‐4 (DPP‐4) inhibitors have been reported to be generally well tolerated. However, angioedema has been reported as one of the rare adverse events of these drugs.Case reportWe report a case in which angioedema induced by vildagliptin disappeared after changing to another DPP‐4 inhibitor, alogliptin.DiscussionOur case
Y, Saisho, H, Itoh
openaire +2 more sources
Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
Clinical Pharmacokinetics, 2012Dipeptidyl peptidase-4 (DPP-4) inhibitors collectively comprise a presently unique form of disease management for persons with type 2 diabetes mellitus. The aim of this review is to compare the clinical pharmacokinetics of available DPP-4 inhibitors (alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin) for the purpose of identifying ...
Larry K, Golightly +2 more
openaire +2 more sources
Bicyclic cyanothiazolidines as novel dipeptidyl peptidase 4 inhibitors
Bioorganic & Medicinal Chemistry Letters, 2009The synthesis and biochemical evaluation of novel cyanothiazolidine inhibitors of dipeptidyl peptidase 4 (DPP4) is described. Their main structural feature is a constrained bicyclic core that prevents the intramolecular formation of inactive cyclic species.
Juan M, Betancort +12 more
openaire +2 more sources
Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties
Expert Opinion on Investigational Drugs, 2006Vildagliptin is a competitive and reversible inhibitor of dipeptidyl peptidase-4. Dipeptidyl peptidase-4 inhibitors act mainly by preventing the rapid degradation of glucagon-like peptide-1. In clinical trials, vildagliptin improves glycaemic control both as monotherapy and in combination with metformin for periods of < or = 52 weeks in subjects with ...
openaire +2 more sources